Scholars LITERATURE

Journal of Clinical Oncology and Therapeutics

Review Article

DOI: https://doi.org/10.47275/2690-5663-140
Volume 7 Issue 1

Clinical Oncology: Focus on Fundamentals, Diagnostic Approaches, Emerging Technologies, and Palliative Care

Jessiya Sathick[1*], Vallepu Rachana[2*], Vittala Rohila[2] and Poka Guru Charan[3]

[1]Madras Medical College, Chennai, Tamil Nadu, India
[2]Mamata Medical College, Khammam, Telangana, India
[3]Sapthagari Institute of Medical Science and Research Centre, Bengaluru, Karnataka, India

Abstract

Clinical oncology focuses on the diagnosis, treatment, and management of cancer, integrating advancements in molecular biology, targeted therapies, immunotherapy, and precision medicine to enhance patient outcomes. The field has seen transformative progress, with therapies increasingly tailored to the genetic and molecular profiles of individual tumors, improving efficacy and minimizing side effects. Innovations in early detection, personalized treatment plans, and multidisciplinary care have significantly impacted survival rates across various cancer types. Despite these advancements, challenges such as treatment resistance, late-stage diagnosis, and access to care persist, requiring ongoing research and global collaboration to address disparities and optimize treatment strategies for diverse patient populations.

Keywords: Diagnostic approaches, Modalities, Clinical research, Imaging techniques, New technologies, Quality of life, Ethical considerations

Correspondence to: Jessiya Sathick and Vallepu Rachana, Madras Medical College, Chennai, Tamil Nadu, India and Mamata Medical College, Khammam, Telangana, India.

Citation: Sathick J, Rachana V, Rohila V, Charan PG (2025) Clinical Oncology: Focus on Fundamentals, Diagnostic Approaches, Emerging Technologies, and Palliative Care. J Clin Oncol Ther, Volume 7:1. 140. DOI: https://doi.org/10.47275/2690-5663-140

Received: November 25, 2024; **Accepted:** January 10, 2025; **Published:** January15, 2025

Introduction

Clinical oncology is an interdisciplinary field encompassing the study and treatment of cancer through medical, radiation, and surgical oncology [1]. Advances in this domain have significantly improved cancer detection, diagnosis, and management. Emerging areas include the integration of artificial intelligence (AI), genetic profiling, and precision medicine in oncology [2, 3]. This comprehensive overview outlines current trends, including the role of imaging, palliative care, and guidelines in clinical practice, alongside technological innovations.

Over the years, several noted publications have implored insights into clinical oncology. Strauss and Conti [4] focuses on the value of positron emission tomography (PET) imaging in diagnosing and managing various cancers. It reviews the applications of PET in clinical settings and its implications for improving outcomes. Hensley et al. [5] presents evidence-based guidelines for the application of chemotherapy and radiotherapy protectants, enhancing safety and efficacy in cancer treatment. Folkman [6] discusses the role of angiogenesis in tumor progression and its potential as a therapeutic target in oncology. Ramaswamy and Golub [7] explores how gene expression profiling using DNA microarrays advances cancer classification and treatment strategies. Crowley and Ankerst [8] a resource on statistical approaches tailored to oncology clinical trials and translational research. Santamaria et al. [9] examines the role of epithelial-mesenchymal transition in metastasis and its implications for future cancer therapies. Hesketh et al. [10] provides updated recommendations on the use of antiemetics in oncology to mitigate chemotherapy-induced nausea and vomiting. Ferrell et al. [11] aims to optimize patient-centered care by incorporating palliative approaches, enhancing quality of life (QoL) and outcomes for oncology patients. Kann et al. [12] reviews the application of AI in oncology, from diagnosis to treatment planning, highlighting challenges and future directions.

Fundamentals of Clinical Oncology

Clinical oncology is the branch of medicine dedicated to the study, diagnosis, and management of cancer [13]. It integrates knowledge from molecular biology, pathology, and pharmacology to provide comprehensive care to patients with malignancies [13]. Cancer arises from genetic and epigenetic alterations that lead to unregulated cell growth, evasion of apoptosis, and metastatic potential [14]. These alterations often involve key molecular pathways, such as those regulated by oncogenes, tumor suppressor genes, and signaling cascades like PI3K/AKT/mTOR and MAPK [14]. Understanding the molecular basis of tumorigenesis is critical for identifying therapeutic targets and improving patient outcomes.

A cornerstone of clinical oncology is the accurate diagnosis and staging of cancer, which guide therapeutic decisions and prognostication [14]. Diagnostic modalities include advanced imaging techniques such as PET, magnetic resonance imaging (MRI),

and computed tomography (CT), alongside histopathological and immunohistochemical analysis. Molecular diagnostics, including next-generation sequencing (NGS) and liquid biopsies, enable the detection of genetic mutations and circulating tumor DNA, providing a non-invasive means to characterize tumors at the genomic level (Figure 1) [15, 16]. Staging systems, like the TNM (Tumor, Node, Metastasis) classification, offer standardized criteria to assess tumor extent and metastatic spread [17].

Therapeutic approaches in oncology are multifaceted and tailored to the individual patient's clinical and molecular profile [17]. Treatment modalities include surgery, radiotherapy, and systemic therapies such as chemotherapy, targeted therapy, and immunotherapy [18]. Advances in precision medicine have enabled the development of therapies that target specific molecular aberrations, such as HER2 inhibitors in breast cancer or EGFR inhibitors in non-small cell lung cancer. Immuno-oncology, involving immune checkpoint inhibitors and Chimeric antigen receptor T-cell (CAR-T) cell therapy, represents a paradigm shift, leveraging the patient's immune system to combat malignancy effectively [19-21].

Beyond treatment, clinical oncology encompasses supportive care and palliative interventions to optimize QoL [22]. This includes addressing oncologic emergencies such as spinal cord compression and tumor lysis syndrome, as well as managing chronic symptoms like cancer-related pain, cachexia, and fatigue. Integrating palliative care early in the disease trajectory has been shown to improve both survival and patient-reported outcomes [22]. As oncology continues to evolve with innovations like AI and liquid biopsies, the field remains at the forefront of personalized medicine and translational research, striving to reduce the global cancer burden [23].

Diagnostic Approaches

Accurate diagnosis is the cornerstone of clinical oncology, enabling the effective management of cancer patients [24]. The diagnostic process begins with clinical evaluation, including a thorough history, physical examination, and assessment of presenting symptoms. Signs such as unintentional weight loss, persistent fatigue, or localized masses often prompt further investigation. Laboratory tests, including complete blood count and serum tumor markers such as carcinoembryonic antigen or prostate-specific antigen, provide biochemical insights that may indicate malignancy. These initial evaluations help narrow down potential diagnoses, guiding more targeted diagnostic modalities [15, 25, 26].

Imaging technologies (Table 1) play a pivotal role in oncology, offering non-invasive methods to detect, characterize, and stage malignancies. CT scans provide high-resolution, cross-sectional images to identify tumor location, size, and extent. MRI excels in soft tissue contrast, making it invaluable for detecting brain, liver, or spinal tumors. PET, often combined with CT (PET/CT), leverages radiotracers like fluorodeoxyglucose to identify metabolically active cancer cells (Figure 2). These modalities are instrumental not only in detecting primary tumors but also in assessing metastatic spread, an essential step in staging [27-29].

Histopathological examination remains the gold standard for cancer diagnosis [30]. Biopsy procedures-such as fine-needle aspiration, core needle biopsy, or excisional biopsy-provide tissue samples for microscopic analysis [31]. Pathologists evaluate cellular morphology, mitotic activity, and histologic grade, offering critical insights into tumor type and aggressiveness [32]. Immunohistochemistry complements this process by detecting specific proteins, such as HER2



Figure 1: Commonly used non-invasive approaches [15].

Table 1: Imaging markers used in cancer early-stage detection [15].

Clinical phase	Clinical role	Approach	Biomarker
-	Melanoma diagnosis	White-light imaging	Mucosal abnormalities
Companion diagnostics evaluated by European Medicines Agency	Diagnosis for platinum-resistant ovarian cancer	Single-photon emission CT	^{99m}Tc-etarfolatide folate receptor-positive
Translational gap 2	Determination of probability of breast cancer in patients with genetic predisposition	MRI	MRI in breast screening category
Translational gap 2	Prostate cancer prognosis	Single-photon emission CT	Bone scan index: (Area of metastasis/area of anatomical region where the metastasis is located) x Coefficient reflecting the regional proportion of skeletal mass
Translational gap 2	Safety marker in breast cancer	Dual-energy X-ray absorptiometry	T-score: Bone mineral density-reference bone mineral density/standard deviation
Translational gap 2	Prognosis for all cancers	PET, CT, and MRI	TNM staging
Translational gap 2	Breast cancer diagnosis	Mammography	Breast morphology



Figure 2: Advanced cancer diagnostic approaches [16].

Table 2: Epigenetic and genetic markers [15].

Biomarker	Cancer	Use	Genes
Epigenetics	Various	Role of histone acetylation	Histone acetylation levels
	Various	Detection of DNA methylation in promoter regions	ITIH5, PER1, SPAG6, NKX2-6, BRCA1, p16, RASSF1A, etc.
RNA	Lung	Detection of circular RNA markers	Has circ 0013958
	Various	Identifying miRNA markers	Various microRNAs
DNA	Various	Monitoring circulating DNA	Tumor DNA circulation
	Various	Detection of mismatch-repair gene mutations	Mismatch-repair gene mutations
	Various	Detection of oncogene alterations	BRCA1/2, RAS, APC, KRAS, p53, etc.
Gene expression	Prostate	Prediction of recurrence after surgery	Decipher
	Breast	Subtype classification and hormone therapy	Prosigna (PAM50-50 genes)
	Breast	Distant metastasis risk and treatment guidance	MammaPrint (18 genes)
	Breast	Recurrence prediction and treatment guidance	Oncotype DX (16 genes)
Gene alterations and mutations	Gliomas	Prognostic and diagnostic markers	IDH mutations
	Gastric/breast	Indication of aggressive behavior	HER2 overexpression/amplification
	Ovarian/breast	Guiding therapy selection	BRCA1/BRCA2 mutations
	Colorectal	Treatment response affect	KRAS mutations (30 - 40% cases)
	NSCLC	EGFR inhibitors sensitivity	EGFR mutations
	Melanoma	Targeted therapy selection	BRAF V600E mutation

or PD-L1, that have diagnostic, prognostic, or therapeutic significance [32]. This integrative approach ensures precise tumor classification and informs subsequent therapeutic strategies [33, 34].

In recent years, molecular diagnostics have revolutionized oncology by enabling the detection of genetic and epigenetic (Table 2) aberrations that drive tumorigenesis [35]. Techniques such as polymerase chain reaction, fluorescence *in situ* hybridization, and NGS facilitate the identification of actionable mutations in genes like EGFR, ALK, and BRAF [36]. Liquid biopsies, which analyze circulating tumor DNA or circulating tumor cells in peripheral blood, offer a non-invasive alternative for genetic profiling [37]. These advancements enable dynamic monitoring of tumor evolution and therapeutic resistance, significantly enhancing personalized medicine.

Lastly, staging systems such as the TNM classification or Ann Arbor staging are integral to diagnostic evaluation, providing a standardized framework for assessing disease extent [38]. These systems quantify tumor size (T), regional lymph node involvement (N), and distant metastases (M), offering a comprehensive overview of disease burden [39]. Radiological tools, combined with sentinel lymph node biopsies or bone marrow aspiration in certain cancers, ensure accurate staging [40]. This not only informs prognosis but also guides treatment planning, facilitating a tailored approach to each patient's oncological care. Through these multifaceted diagnostic approaches, clinical oncology continues to advance towards earlier detection, precise classification, and optimized outcomes.

Modalities of Cancer Treatment

Cancer treatment in clinical oncology employs a multidisciplinary approach that integrates various therapeutic modalities, tailored to the type, stage, and molecular characteristics of the malignancy [41]. The primary goals of cancer treatment are to achieve tumor eradication, prolong survival, and improve QoL [42]. Treatment selection depends on tumor biology, patient performance status, and comorbidities, often requiring collaboration among medical, surgical, and radiation oncologists. Advances in understanding tumorigenesis and host-tumor interactions have led to the development of innovative therapies, broadening the spectrum of treatment options available [43, 44].

Surgical oncology forms the cornerstone of treatment for many solid tumors, particularly in early-stage disease [45]. Surgical resection involves removing the primary tumor with clear margins to reduce

the risk of local recurrence. Techniques such as sentinel lymph node biopsy are often employed to assess nodal involvement in cancers like breast carcinoma and melanoma [46, 47]. In certain cases, neoadjuvant therapy-chemotherapy or radiotherapy administered before surgery-aims to downstage tumors, improving resectability. Advances in minimally invasive techniques, including robotic-assisted surgery, have reduced morbidity while maintaining oncologic outcomes [48, 49].

Radiation oncology utilizes high-energy ionizing radiation to target and destroy cancer cells while sparing surrounding normal tissue [50]. Techniques such as intensity-modulated radiation therapy and stereotactic body radiotherapy allow for precise dose delivery, minimizing toxicity. Proton therapy, an emerging modality, is particularly beneficial for pediatric and head-and-neck cancers due to its ability to limit radiation exposure to adjacent structures [51]. Palliative radiotherapy is frequently employed to relieve symptoms, such as pain from bone metastases or neurological deficits from spinal cord compression [52].

Systemic therapy is a central pillar of oncology, encompassing chemotherapy, targeted therapy, immunotherapy, and hormonal therapy [53]. Chemotherapy, a traditional approach, uses cytotoxic agents to interfere with cell division, often as part of adjuvant or palliative regimens. While effective, chemotherapy is associated with systemic toxicity, prompting the development of targeted therapies that inhibit specific molecular pathways [54, 55]. Examples include tyrosine kinase inhibitors like imatinib for chronic myeloid leukemia and HER2 inhibitors like trastuzumab for HER2-positive breast cancer [56]. These therapies enhance efficacy while reducing off-target effects.

Immunotherapy represents (Table 3) a transformative advancement, harnessing the immune system to combat cancer. Immune checkpoint inhibitors, such as pembrolizumab (anti-PD-1) and ipilimumab (anti-CTLA-4), block immune suppressive pathways, enabling T-cell activation. CAR-T cell therapy, another breakthrough, involves engineering patient-derived T cells to target specific tumor antigens [57-59]. While highly effective in hematologic malignancies, these therapies can induce immune-related adverse events, necessitating vigilant management. Cancer vaccines and oncolytic viruses are also being explored as adjunctive immunotherapeutic strategies [60, 61].

Lastly, combination therapies and multimodal approaches are increasingly used to exploit the synergistic effects of various treatments. For example, chemoradiotherapy combines systemic agents with radiotherapy to enhance tumor cytotoxicity, commonly used in locally advanced cervical and rectal cancers [62, 63]. Emerging therapies, including nanoparticle drug delivery systems and gene-editing technologies like CRISPR, promise to further refine cancer treatment [64]. The integration of precision oncology and molecular profiling allows clinicians to tailor therapies based on tumor-specific biomarkers, maximizing therapeutic benefit while minimizing toxicity [65].

Through these diverse modalities, clinical oncology continues to evolve, offering hope for improved survival and QoL for cancer patients. The integration of traditional and novel therapies underscores the field's commitment to advancing cancer care while addressing individual patient needs. By leveraging technological innovation and molecular insights, clinicians aim to deliver personalized, effective, and compassionate cancer treatment.

Clinical Trials and Research

Clinical trials are a cornerstone of progress in clinical oncology, providing the evidence base for new diagnostic tools, therapeutic agents, and management protocols. These trials follow rigorous protocols and are typically categorized into four phases, each with distinct objectives. Phase I trials focus on evaluating the safety, tolerability, and pharmacokinetics of investigational agents, often in patients with refractory cancers. Phase II trials assess efficacy and further safety, while phase III compares new interventions against the standard of care in larger patient populations. Finally, phase IV trials monitor long-term safety and effectiveness post-approval [66-68]. Figure 3 presents schematic representation of clinical trials timeline in precision oncology [69].

For example, phase I trial of CAR-T cell therapy for relapsed/refractory B-cell malignancies demonstrated feasibility and manageable toxicity, paving the way for further development [70]. Similarly, the CheckMate-227 trial, a phase III study, compared nivolumab plus ipilimumab (immune checkpoint inhibitors) against chemotherapy in NSCLC, leading to approval for first-line treatment [71].

Innovations in trial design

Modern oncology trials incorporate innovative designs to accelerate the evaluation process and address the heterogeneity of cancer. Basket trials test a single drug across multiple cancers sharing a common biomarker, such as the NCI-MATCH trial investigating molecularly targeted therapies in biomarker-positive tumors. Umbrella trials, on the other hand, evaluate multiple therapies within a single cancer type based on molecular subtypes, exemplified by the Lung-MAP study for NSCLC. These adaptive designs optimize patient selection and streamline drug development [69, 72].

For example, the I-SPY 2 trial in breast cancer, an adaptive trial, assigns patients to experimental therapies based on tumor characteristics, expediting drug approvals [73]. Another example is the KEYNOTE-012 study, which explored pembrolizumab in various cancers with high PD-L1 expression [74].

Translational research

Translational research bridges the gap between bench and bedside, converting laboratory discoveries into clinical applications [75]. In

Table 3: FDA approved immunotherapies [15].

Immunotherapy	Benefit to patients with	Cancer
Ipilimumab + Nivolumab and Pembrolizumab	Microsatellite instability-high/dMMR	Colorectal
Nivolumab and Pembrolizumab	Classic Hodgkin lymphoma	Hodgkin lymphoma
Axitinib + Avelumab, Pembrolizumab + Axitinib, Pembrolizumab, and Nivolumab	Metastatic renal cell carcinoma	Kidney
Nivolumab, Pembrolizumab, and Atezolizumab	Locally advanced or metastatic urothelial carcinoma	Bladder
Nivolumab and Pembrolizumab	Recurrent or metastatic squamous cell carcinoma	Head and neck
Chemotherapy + Pembrolizumab, Durvalumab (Imfinzi), Atezolizumab (Tecentriq), Nivolumab, and Pembrolizumab	NSCLC	Lung
Ipilimumab (Yervoy), Nivolumab (Opdivo), and Pembrolizumab (Keytruda)	Advanced and metastatic melanoma	Melanoma



Figure 3: Clinical trials timeline in precision oncology [69].

oncology, this often involves preclinical studies on molecular targets, followed by clinical trials evaluating targeted therapies [76]. One notable example is the development of imatinib, a tyrosine kinase inhibitor for chronic myeloid leukemia. Translational efforts identified the BCR-ABL fusion gene as the driver mutation, leading to the drug's rapid progression from concept to clinical use [77].

For example, translational research was also pivotal in developing PARP inhibitors for BRCA-mutated breast and ovarian cancers, and EGFR inhibitors like erlotinib for NSCLC, demonstrating the value of targeted therapeutic development [78, 79].

Patient-centered research

Clinical trials increasingly focus on patient-centered outcomes, emphasizing QoL, patient-reported outcomes, and survivorship [80]. QoL assessments evaluate treatment impacts on physical, emotional, and social well-being, guiding holistic care [81]. For instance, trials of palliative interventions often prioritize symptom relief over tumor control, such as studies on opioids for cancer pain management [82].

For example, ENABLE III trial demonstrated the benefits of early palliative care integration on QoL and survival in advanced cancer patients [83]. Similarly, studies on scalp cooling systems showed significant reduction in chemotherapy-induced alopecia, improving patients' psychosocial well-being [84].

Ethics and diversity in trials

Ethical considerations and diversity are critical in clinical oncology research [85]. Ensuring informed consent, protecting vulnerable populations, and balancing risk-benefit ratios are fundamental [86]. However, disparities in trial participation remain a challenge, with underrepresentation of minorities and older adults limiting generalizability [87]. Efforts to improve inclusivity include community-based recruitment and decentralized trials utilizing telehealth.

For example, the TAILORx trial, evaluating gene-expression assays to tailor breast cancer treatment, successfully enrolled a diverse cohort, providing data applicable across demographics [88]. Initiatives like the Food and Drug Administration's (FDA) project equity aim to reduce disparities and improve representation in cancer trials [89, 90].

Post-trial implications

The findings from clinical trials directly influence clinical practice and guidelines, making them pivotal for advancing oncology care [11]. Successful trials often lead to the approval of breakthrough therapies, while negative trials refine our understanding of treatment limitations [91, 92]. Importantly, trials generate valuable biobanks and datasets, enabling further research.

For example, trials like MONALEESA-2 (ribociclib in breast cancer) have led to paradigm shifts in oncology [93]. Negative trials, such as those evaluating single-agent checkpoint inhibitors in microsatellite-stable colorectal cancer, underscore the need for combination approaches.

In summary, through robust clinical trials and translational research, clinical oncology continuously evolves, addressing the complexities of cancer while striving to deliver evidence-based, patient-centered care.

Emerging Technologies

Emerging technologies in clinical oncology are revolutionizing cancer care, improving diagnostic precision, treatment efficacy, and patient outcomes [94]. These advancements leverage innovations in molecular biology, AI, imaging, and therapeutics, enabling personalized and targeted approaches to oncologic management. Here, we explore key emerging technologies with scientific explanations and examples of their applications.

AI in oncology

AI has become a transformative tool in cancer detection, diagnosis, and treatment planning. Machine learning algorithms analyze large datasets, identifying subtle patterns and anomalies that may indicate malignancy. For example, deep learning models applied to mammograms have demonstrated performance on par with radiologists in detecting breast cancer. AI is also used for predicting treatment responses and tailoring therapies based on patient-specific data, optimizing outcomes while reducing overtreatment [95-97].

Liquid biopsies

Liquid biopsies offer a non-invasive method to detect and monitor cancer through the analysis of circulating tumor DNA and circulating tumor cells in blood samples. This technology enables early detection, real-time tracking of tumor evolution, and identification of treatment resistance mechanisms. For instance, Guardant360 is a clinically validated liquid biopsy assay used to detect actionable mutations in non-small cell lung cancer (NSCLC) [98-100].

NGS

NGS has transformed molecular oncology by allowing comprehensive profiling of genetic alterations in tumors. This high-throughput technology identifies mutations, fusions, and copy number variations across cancer-related genes. Clinical applications include identifying actionable targets for therapies, such as EGFR mutations in NSCLC or BRCA mutations in breast and ovarian cancers. NGS-based companion diagnostics are now integral to precision oncology [101, 102].

Radiomics and imaging biomarkers

Radiomics involves extracting quantitative features from medical

images (CT, MRI, or PET) to predict tumor characteristics and treatment responses (Figure 2). For example, radiomics has been used to stratify patients with glioblastoma based on tumor heterogeneity, correlating image-derived features with genetic markers. Imaging biomarkers such as metabolic activity on PET scans provide additional insights into tumor biology and guide treatment strategies [103, 104].

CRISPR-Cas9 and gene editing

Gene-editing technologies like CRISPR-Cas9 enable precise modification of genomic sequences, offering therapeutic potential in oncology. CRISPR-based approaches are being explored to edit cancer-associated genes, enhance T-cell receptor specificity, and disrupt immune evasion pathways. Clinical trials are investigating CRISPR-engineered T-cells for treating hematological malignancies, including leukemia and lymphoma [105-107].

Nanotechnology in drug delivery

Nanotechnology enhances drug delivery by improving the bioavailability and targeting of therapeutic agents. Nanoparticles can be engineered to deliver chemotherapeutics directly to tumor cells, minimizing systemic toxicity. For example, liposomal formulations such as Doxil (liposomal doxorubicin) improve the pharmacokinetics and reduce side effects of traditional chemotherapy drugs. Emerging nanocarriers include stimuli-responsive nanoparticles that release drugs in response to tumor-specific triggers [108, 109].

Immunotherapeutic innovations

Advancements in immunotherapy include bispecific T-cell engagers (BiTEs), oncolytic viruses, and novel checkpoint inhibitors [110]. BiTEs, such as blinatumomab, redirect T-cells to target tumor antigens, enhancing immune-mediated tumor destruction. Oncolytic viruses, genetically engineered to selectively infect and kill cancer cells, also stimulate anti-tumor immunity. Additionally, new checkpoint inhibitors targeting molecules like LAG-3 and TIGIT are expanding the scope of immuno-oncology [111].

Organoids and tumor-on-a-chip models

Patient-derived organoids (PDOs) and tumor-on-a-chip technologies provide *ex vivo* models for studying tumor behavior and drug responses. PDOs, grown from cancer patient tissues, mimic the 3D architecture and heterogeneity of tumors, allowing personalized drug screening. Tumor-on-a-chip platforms incorporate microfluidics to replicate the tumor microenvironment, facilitating studies on metastasis and therapy resistance [112, 113].

Wearable and remote monitoring devices

Wearable technologies, such as biosensors, enable continuous monitoring of vital signs and treatment-related side effects in oncology patients. Devices like wearable ECG monitors detect chemotherapy-induced cardiotoxicity early, while digital health platforms track patient-reported outcomes remotely. Such technologies empower patients and improve clinical decision-making in real time [114-116].

Quantum computing in oncology research

Quantum computing holds promise for solving complex problems in cancer biology and drug discovery. By simulating molecular interactions and predicting protein-ligand binding with high accuracy, quantum algorithms accelerate the development of targeted therapies. While still in its infancy, quantum computing has the potential to revolutionize oncology research by optimizing biomarker discovery and predictive modeling [117, 118].

In summary, these emerging technologies exemplify the intersection of cutting-edge science and clinical practice in oncology. By integrating these advancements, clinicians can enhance the precision of cancer care, improve therapeutic outcomes, and ultimately reduce the burden of cancer globally.

Palliative Care

Palliative care in clinical oncology focuses on improving the QoL for patients with advanced or terminal malignancies [119]. It is a multidisciplinary approach that addresses physical, emotional, psychological, social, and spiritual needs. Unlike curative treatments, palliative care prioritizes symptom management and patient comfort rather than achieving remission. Scientific evidence has established that early integration of palliative care alongside standard oncologic treatments enhances not only patient well-being but also clinical outcomes, including survival and caregiver satisfaction (Figure 4) [120, 121].

Symptom management is a cornerstone of palliative care, targeting the common distressing symptoms experienced by oncology patients. Cancer pain, often resulting from tumor invasion, inflammation, or treatment side effects, is managed using the World Health Organization (WHO) analgesic ladder [122, 123]. This approach escalates treatment from non-opioids to opioids as needed, often supplemented by adjuvant medications such as corticosteroids and anticonvulsants for neuropathic pain. Additionally, interventions like nerve blocks or palliative radiotherapy can be used for refractory pain. Symptom-



Figure 4: Evolution of palliative care [22].

focused care also addresses issues like dyspnea, cachexia, fatigue, and nausea, leveraging pharmacologic and non-pharmacologic strategies [124].

Psychological and emotional support are integral to palliative oncology. The diagnosis and progression of cancer often lead to anxiety, depression, and existential distress [125]. Palliative care teams, including psychologists and social workers, employ evidence-based therapies such as cognitive-behavioral therapy and mindfulness-based interventions to alleviate psychological suffering [126]. For patients with existential distress, meaning-centered psychotherapy helps them find purpose and value during advanced stages of illness. Pharmacological management, such as the use of antidepressants or anxiolytics, may also be necessary for severe cases [127].

Family and caregiver support is another essential aspect of palliative oncology. Cancer's impact extends beyond the patient to their loved ones, who often face caregiver fatigue and emotional burden. Palliative care teams provide counseling, education on symptom management, and respite care services to mitigate these challenges. Structured communication frameworks, such as the SPIKES protocol, are used to convey complex medical information compassionately, facilitating shared decision-making and aligning care goals with patient and family values [128, 129].

Scientific advancements in palliative oncology also encompass the integration of specialized interventions such as palliative sedation for intractable symptoms and ethical considerations surrounding end-of-life care [130]. Emerging evidence supports the use of telehealth for delivering palliative services, increasing accessibility in underserved regions [131]. Moreover, integrating palliative care early in the treatment trajectory-often from the time of diagnosis has demonstrated improved patient satisfaction and reduced healthcare costs by minimizing unnecessary hospitalizations and aggressive interventions in terminal stages.

Palliative care in clinical oncology represents a holistic, patient-centered approach that complements curative efforts and addresses the comprehensive needs of patients and families [129]. By emphasizing comfort, dignity, and respect, it embodies the essence of compassionate oncology practice, fostering a better QoL regardless of disease progression [130].

Preventive Measures

Preventive oncology focuses on strategies to reduce the incidence of cancer through lifestyle interventions, vaccinations, early detection, and risk-reduction approaches [132]. This proactive discipline addresses modifiable and non-modifiable risk factors to curb the cancer burden. According to the WHO, approximately 30 - 50% of cancers are preventable by adopting preventive measures, underscoring their critical role in public health and oncology [133].

Lifestyle interventions and cancer prevention

Lifestyle modifications, including dietary changes, physical activity, and smoking cessation, significantly lower cancer risk. Tobacco use is the leading cause of cancer worldwide, responsible for approximately 22% of cancer deaths, as reported by the WHO. Similarly, excessive alcohol consumption accounts for 6% of global cancer cases, particularly linked to liver, esophageal, and breast cancers. Obesity, another modifiable factor, contributes to 13 different types of cancer, including endometrial, colorectal, and pancreatic cancers [133].

The American Cancer Society (ACS) notes that regular physical activity can reduce breast cancer risk by 12% and colorectal cancer risk by 24%. A healthy diet, rich in fruits and vegetables, is associated with a 10 to 20% reduction in overall cancer risk [133].

Cancer vaccinations as a preventive measure

Vaccination against oncogenic viruses, such as Human Papillomavirus (HPV) and Hepatitis B Virus (HBV), has demonstrated significant reductions in cancer incidence [134]. HPV vaccination, targeting strains responsible for 70% of cervical cancers, also protects against oropharyngeal and anal cancers. Similarly, HBV vaccination reduces hepatocellular carcinoma risk by 60 - 70% in high-prevalence regions [135].

Global HPV vaccination programs have achieved a 90% reduction in HPV infections in vaccinated populations. The WHO estimates that full-scale HPV vaccination could prevent 4.5 million cervical cancer cases by 2030 [135].

Screening and early detection

Cancer screening facilitates the identification of precancerous lesions or early-stage cancers, improving survival rates and reducing treatment complexity. Mammography for breast cancer, colonoscopy for colorectal cancer, and low-dose CT for lung cancer are well-established screening modalities [138]. Early detection significantly impacts prognosis, with cervical cancer screening reducing mortality by 80% in high-resource settings [137].

The National Cancer Institute reports that colorectal cancer screening has reduced mortality by 50% over the past 30 years. Lung cancer screening in high-risk populations can reduce mortality by 20%, according to the National Lung Screening Trial [138].

Risk reduction strategies

Preventive oncology also includes pharmacological and surgical risk-reduction approaches for high-risk individuals. For instance, tamoxifen and raloxifene are used in chemoprevention for breast cancer, reducing risk by 40 to 50% in women with elevated risk profiles [138]. Prophylactic surgeries, such as bilateral mastectomy and salpingo-oophorectomy, are lifesaving for individuals with BRCA1/2 mutations, reducing breast and ovarian cancer risk by over 90% [139, 140].

The United States Preventive Services Task Force recommends chemoprevention for women at high risk of breast cancer, citing studies that show a 46% reduction in breast cancer incidence over five years [141].

Environmental and occupational exposure reduction

Preventive oncology also addresses environmental and occupational carcinogens [142]. Policies targeting air pollution, asbestos exposure, and industrial carcinogens like benzene and formaldehyde have reduced exposure-related cancers [143]. For instance, radon mitigation in residential areas lowers the risk of lung cancer, particularly among non-smokers [143].

Air pollution, classified as a group 1 carcinogen by the International Agency for Research on Cancer, is responsible for 4.2 million premature deaths annually, including 7 - 10% of lung cancer cases [144, 145]. Workplace regulations have reduced mesothelioma incidence from asbestos exposure by over 40% in regulated industries [146].

Impact of preventive oncology

The economic and social benefits of preventive oncology are substantial. By preventing cancer cases, healthcare systems save on the costs of diagnosis and treatment [147]. The Economic Modelling for Cancer Prevention study estimates that every US$1 spent on cancer prevention yields a US$4 return in healthcare savings [148]. Moreover, public health campaigns like anti-tobacco initiatives have significantly reduced smoking rates globally, contributing to declining lung cancer mortality in several countries [149].

In summary, preventive oncology represents a cost-effective and impactful strategy to reduce cancer incidence and mortality. By integrating lifestyle changes, vaccinations, early screening, and targeted risk reduction, the field aims to mitigate the global cancer burden, enhancing population health outcomes.

Ethical and Economic Aspects

Clinical oncology is inherently complex, intertwining scientific advancements with ethical dilemmas and economic considerations. The rapid evolution of treatments, such as targeted therapies and immunotherapy, has improved survival rates but also raised challenging questions about equitable access, cost sustainability, and patient autonomy [150, 151]. Addressing these aspects is critical to delivering ethical, inclusive, and economically viable cancer care.

Ethical challenges in oncology care

Ethical dilemmas in oncology frequently revolve around balancing the principles of beneficence, non-maleficence, autonomy, and justice. One of the most prominent ethical issues is ensuring informed consent. Oncology treatments are often accompanied by significant risks and uncertain outcomes [152, 153]. Patients must fully understand the potential benefits, side effects, and alternative options [154]. For example, in clinical trials, ensuring that participants comprehend experimental nature and potential risks is vital to upholding ethical standards.

Another ethical challenge is end-of-life care. Decisions about discontinuing aggressive treatments or transitioning to palliative care require sensitivity to patients' wishes, cultural considerations, and medical realities [155, 156]. Tools like advanced directives and shared decision-making frameworks help navigate these emotionally charged situations, promoting autonomy and dignity [157].

Equity and accessibility

Justice in oncology care involves ensuring equitable access to diagnosis and treatment across populations [158]. Significant disparities exist in cancer care based on socioeconomic status, geographic location, and race [159]. For instance, individuals in low- and middle-income countries (LMIC) face barriers to accessing advanced therapies like CAR-T cells or checkpoint inhibitors due to high costs and limited infrastructure [160]. Telemedicine and decentralized care models are emerging solutions, aiming to bridge these gaps.

In clinical trials, underrepresentation of minority populations poses another ethical concern, limiting the generalizability of findings [161]. Efforts like the FDA's project equity and community-based recruitment aim to ensure inclusiveness in research, promoting justice in evidence generation and application [162].

Economic challenges

The rising costs of cancer care, driven by expensive diagnostic technologies and breakthrough therapies, pose a significant burden on healthcare systems and patients [163]. The ACS reports that annual cancer care costs in the US exceeded $200 billion in recent years, with innovative treatments like CAR-T therapy costing over $373,000 per patient [164]. These figures highlight the financial toxicity faced by patients, encompassing direct costs (treatment and hospitalization) and indirect costs (lost income and caregiving).

High out-of-pocket expenses exacerbate disparities, leading many patients to forgo or delay treatment. Value-based care models, which focus on outcomes rather than the volume of services, are being explored as a solution to improve affordability and optimize resource allocation [165].

Balancing innovation with affordability

Pharmaceutical innovation brings ethical and economic tensions. While new drugs extend survival and improve QoL, their high prices often restrict accessibility [166]. Ethical questions arise about the pricing models of oncology drugs, with calls for transparency in research and development costs [167]. For example, initiatives like value-based pricing aim to align drug prices with their clinical benefit, measured by metrics such as quality-adjusted life years [168].

Economic incentives, such as expedited regulatory pathways and orphan drug designations, are designed to encourage innovation for rare cancers. However, ensuring that these incentives do not disproportionately favor profitability over accessibility is a continuing challenge for policymakers.

Ethical implications of emerging technologies

Emerging technologies in oncology, such as AI and genomic medicine, bring ethical dilemmas regarding data privacy, bias, and equitable access [169]. AI models trained on non-representative datasets risk perpetuating existing healthcare disparities, while genetic testing raises questions about consent, confidentiality, and the psychological impact of risk information. Ethical frameworks are essential to guide the development and deployment of these technologies, ensuring that benefits are distributed fairly [170].

Global efforts toward ethical and economic balance

International organizations like the WHO and Union for International Cancer Control advocate for ethical and economically sustainable cancer care [171]. Programs such as access accelerated aim to increase the availability of cancer medications in LMICs. Additionally, value frameworks, like those developed by the American Society of Clinical Oncology, provide tools for assessing the cost-effectiveness of treatments, guiding clinicians and policymakers in resource allocation [172, 173].

In summary, the ethical and economic dimensions of clinical oncology require thoughtful consideration to ensure that advancements in cancer care are both inclusive and sustainable. Balancing innovation with equity and cost-efficiency is essential for creating systems that serve the diverse needs of cancer patients globally while upholding the core principles of medical ethics.

Conclusions

Clinical oncology, the field dedicated to diagnosing and treating cancer, continues to evolve rapidly, with significant advances in targeted therapies, immunotherapy, and personalized medicine. These innovations have transformed the landscape of cancer treatment,

offering patients more effective and less toxic options. The increasing precision of diagnostic tools, including genetic and molecular profiling, has led to more accurate predictions of treatment responses, enabling clinicians to tailor therapies to the individual needs of patients. Furthermore, the development of novel drugs and combination therapies has improved survival rates for many types of cancer, offering hope for better outcomes, even in previously hard-to-treat cancers.

However, challenges remain in clinical oncology, particularly in overcoming cancer's complexity and heterogeneity. Despite the promising advancements, treatment resistance, side effects, and the development of new cancer subtypes present ongoing hurdles. Early detection and prevention continue to be critical aspects of improving survival rates, yet disparities in access to care, especially in low-resource settings, persist. As the field progresses, it will be essential to continue bridging these gaps, ensuring that the benefits of new treatments reach all populations. Moreover, ongoing research, collaboration, and a holistic approach that integrates the psychological, social, and physical aspects of cancer care will be crucial to achieving the ultimate goal of curing more cancers and improving the QoL for patients.

Acknowledgements

None.

Conflict of Interest

None.

References

1. Witt CM, Balneaves LG, Cardoso MJ, Cohen L, Greenlee H, et al. (2017) A comprehensive definition for integrative oncology. J Natl Cancer Inst Monograph 2017: 3-8. https://doi.org/10.1093/jncimonographs/lgx012
2. Xu J, Yang P, Xue S, Sharma B, Sanchez-Martin M, et al. (2019) Translating cancer genomics into precision medicine with artificial intelligence: applications, challenges and future perspectives. Hum Genet 138: 109-124. https://doi.org/10.1007/s00439-019-01970-5
3. Dlamini Z, Francies FZ, Hull R, Marima R (2020) Artificial intelligence (AI) and big data in cancer and precision oncology. Comput Struct Biotechnol J 18: 2300-2311. https://doi.org/10.1016/j.csbj.2020.08.019
4. Strauss LG, Conti PS (1991) The applications of PET in clinical oncology. J Nucl Med 32: 623-648.
5. Hensley ML, Schuchter L, Lindley C, Meropol N, Cohen G, et al. (1999) American society of clinical oncology clinical practice guidelinesfor the use of chemotherapy and radiotherapy protectants. J Clin Oncol 17: 3333-3355. https://doi.org/10.1200/JCO.1999.17.10.3333
6. Folkman J (1996) New perspectives in clinical oncology from angiogenesis research. Eur J Cancer 32: 2534–2539. https://doi.org/10.1016/S0959-8049(96)00423-6
7. Ramaswamy S, Golub TR (2002) DNA microarrays in clinical oncology. J Clin Oncol 20: 1932-1941. https://doi.org/10.1200/JCO.2002.20.7.1932
8. Crowley J, Ankerst DP (2005) Handbook of statistics in clinical oncology. Chapman & Hall/CRC.
9. Santamaria PG, Moreno-Bueno G, Portillo F, Cano A (2017) EMT: present and future in clinical oncology. Mol Oncol 11: 718-738. https://doi.org/10.1002/1878-0261.12091
10. Hesketh PJ, Kris MG, Basch E, Bohlke K, Barbour SY, et al. (2017) Antiemetics: American society of clinical oncology clinical practice guideline update. J Clin Oncol 35: 3240-3261. https://doi.org/10.1200/JCO.2017.74.4789
11. Ferrell BR, Temel JS, Temin S, Alesi ER, Balboni TA, et al. (2017) Integration of palliative care into standard oncology care: American society of clinical oncology clinical practice guideline update. J Clin Oncol 35: 96-112. https://doi.org/10.1200/JCO.2016.70.1474
12. Kann BH, Hosny A, Aerts HJ (2021) Artificial intelligence for clinical oncology. Cancer Cell 39: 916-927. https://doi.org/10.1016/j.ccell.2021.04.002
13. Berman R, Davies A, Cooksley T, Gralla R, Carter L, et al. (2020) Supportive care: an indispensable component of modern oncology. Clin Oncol 32: 781-788. https://doi.org/10.1016/j.clon.2020.07.020
14. Ozyerli-Goknar E, Bagci-Onder T (2021) Epigenetic deregulation of apoptosis in cancers. Cancers 13: 3210. https://doi.org/10.3390/cancers13133210
15. Das S, Dey MK, Devireddy R, Gartia MR (2023) Biomarkers in cancer detection, diagnosis, and prognosis. Sensors 24: 37. https://doi.org/10.3390/s24010037
16. Pulumati A, Pulumati A, Dwarakanath BS, Verma A, Papineni RV (2023) Technological advancements in cancer diagnostics: improvements and limitations. Cancer Rep 6: e1764. https://doi.org/10.1002/cnr2.1764
17. Benson JR (2003) The TNM staging system and breast cancer. Lancet Oncol 4: 56-60. https://doi.org/10.1016/S1470-2045(03)00961-6
18. Pestana RC, Ibrahim NK (2021) Cancer treatment modalities systemic and locoregional approaches: challenges and opportunities of multidisciplinary approaches. In Wong FC (ed) Locoregional Radionuclide Cancer Therapy. Springer, pp 17-37.
19. Mechahougui H, Gutmans J, Colarusso G, Gouasmi R, Friedlaender A (2024) Advances in personalized oncology. Cancers 16: 2862. https://doi.org/10.3390/cancers16162862
20. Hays P (2021) Trends in precision oncology and precision medicine 2.0. In Advancing Healthcare Through Personalized Medicine. Springer, pp 419-480.
21. AlDoughaim M, AlSuhebany N, AlZahrani M, AlQahtani T, AlGhamdi S, et al. (2024) Cancer biomarkers and precision oncology: a review of recent trends and innovations. Clin Med Insights Oncol 18: 11795549241298541. https://doi.org/10.1177/11795549241298541
22. Hugar LA, Wulff-Burchfield EM, Winzelberg GS, Jacobs BL, Davies BJ (2021) Incorporating palliative care principles to improve patient care and quality of life in urologic oncology. Nat Rev Urol 18: 623-635. https://doi.org/10.1038/s41585-021-00491-z
23. Fu SW, Tang C, Tan X, Srivastava S (2024) Liquid biopsy for early cancer detection: technological revolutions and clinical dilemma. Expert Rev Mol Diagn 24: 937-955. https://doi.org/10.1080/14737159.2024.2408744
24. Borkar S, Chakole S, Prasad R, Bansod S (2024) Revolutionizing oncology: a comprehensive review of digital health applications. Cureus 16: 1-10. https://doi.org/10.7759/cureus.59203
25. Desai S, Guddati AK (2023) Carcinoembryonic antigen, carbohydrate antigen 19-9, cancer antigen 125, prostate-specific antigen and other cancer markers: a primer on commonly used cancer markers. World J Oncol 14: 4-14. https://doi.org/10.14740/wjon1425
26. Trapé J, Fernández-Galán E, Auge JM, Carbonell-Prat M, Filella X, et al. (2024) Oncology biomarkers section of the catalan association of clinical laboratory science. Factors influencing blood tumor marker concentrations in the absence of neoplasia. Tumor Biol 46: 35-63. https://doi.org/10.3233/TUB-220023
27. Rai HM, Yoo J, Razaque A (2024) A depth analysis of recent innovations in non-invasive techniques using artificial intelligence approach for cancer prediction. Med Biol Eng Comput 62: 3555-3580. https://doi.org/10.1007/s11517-024-03158-0
28. Zakari S, Niels NK, Olagunju GV, Nnaji PC, Ogunniyi O, et al. (2024) Emerging biomarkers for non-invasive diagnosis and treatment of cancer: a systematic review. Front Oncol 14: 1405267. https://doi.org/10.3389/fonc.2024.1405267
29. Soglia S, Pérez-Anker J, Lobos Guede N, Giavedoni P, Puig S, et al. (2022) Diagnostics using non-invasive technologies in dermatological oncology. Cancers 14: 5886. https://doi.org/10.3390/cancers14235886
30. Echle A, Rindtorff NT, Brinker TJ, Luedde T, Pearson AT, et al. (2021) Deep learning in cancer pathology: a new generation of clinical biomarkers. Br J Cancer 124: 686-696. https://doi.org/10.1038/s41416-020-01122-x
31. Davri A, Birbas E, Kanavos T, Ntritsos G, Giannakeas N, et al. (2022) Deep learning on histopathological images for colorectal cancer diagnosis: a systematic review. Diagnostics 12: 837. https://doi.org/10.3390/diagnostics12040837
32. Combalia A, Carrera C (2020) Squamous cell carcinoma: an update on diagnosis and treatment. Dermatol Pract Concept 10: e2020066. http://orcid.org/0000-0003-1608-8820
33. Siddiqui S, Bari V (2021) Accuracy of MRI pelvis in the diagnosis of ovarian endometrioma: using histopathology as gold standard. Cureus 13: 1-7. https://doi.org/10.7759/cureus.20650
34. Azad H, Ahmed A, Zafar I, Bhutta MR, Rabbani MA, et al. (2022) X-ray and MRI correlation of bone tumors using histopathology as gold standard. Cureus 14: 1-9. https://doi.org/10.7759/cureus.27262

35. Ahmad E, Ali A, Sharma AK, Ahmed F, Dar GM, et al. (2022) Molecular approaches in cancer. Clin Chim Acta 537: 60-73. https://doi.org/10.1016/j.cca.2022.09.027

36. Bruno R, Fontanini G (2020) Next generation sequencing for gene fusion analysis in lung cancer: a literature review. Diagnostics 10: 521. https://doi.org/10.3390/diagnostics10080521

37. Russano M, Napolitano A, Ribelli G, Iuliani M, Simonetti S, et al. (2020) Liquid biopsy and tumor heterogeneity in metastatic solid tumors: the potentiality of blood samples. J Exp Clin Cancer Res 39: 1-3. https://doi.org/10.1186/s13046-020-01601-2

38. Tinland J, Gauld C, Sujobert P, Giroux É (2024) Diagnostic staging and stratification in psychiatry and oncology: clarifying their conceptual, epistemological and ethical implications. Med Health Care Philos 27: 333-347. https://doi.org/10.1007/s11019-024-10207-w

39. du Bois H, Heim TA, Lund AW (2021) Tumor-draining lymph nodes: at the crossroads of metastasis and immunity. Sci Immunol 6: eabg3551. https://doi.org/10.1126/sciimmunol.abg3551

40. Marino MA, Avendano D, Zapata P, Riedl CC, Pinker K (2020) Lymph node imaging in patients with primary breast cancer: concurrent diagnostic tools. Oncologist 25: 231-242. https://doi.org/10.1634/theoncologist.2019-0427

41. Shams M, Abdallah S, Alsadoun L, Hamid YH, Gasim R, et al. (2023) Oncological horizons: the synergy of medical and surgical innovations in cancer treatment. Cureus 15: 1-7. https://doi.org/10.7759/cureus.49249

42. Nandini DB, Rao RS, Hosmani J, Khan S, Patil S, et al. (2020) Novel therapies in the management of oral cancer: an update. Disease-a-Month 66: 101036. https://doi.org/10.1016/j.disamonth.2020.101036

43. Queen J, Shaikh F, Sears CL (2023) Understanding the mechanisms and translational implications of the microbiome for cancer therapy innovation. Nat Cancer 4: 1083-1094. https://doi.org/10.1038/s43018-023-00602-2

44. Edsjö A, Holmquist L, Geoerger B, Nowak F, Gomon G, et al. (2023) Precision cancer medicine: concepts, current practice, and future developments. J Intern Med 294: 455-481. https://doi.org/10.1111/joim.13709

45. Najafi M, Majidpoor J, Toolee H, Mortezaee K (2021) The current knowledge concerning solid cancer and therapy. J Biochem Mol Toxicol 35: e22900. https://doi.org/10.1002/jbt.22900

46. Morrison S, Han D (2021) Re-evaluation of sentinel lymph node biopsy for melanoma. Curr Treat Opt Oncol 22: 1-9. https://doi.org/10.1007/s11864-021-00819-2

47. Giammarile F, Vidal-Sicart S, Paez D, Pellet O, Enrique EL, et al. (2022) Sentinel lymph node methods in breast cancer. Semin Nucl Med 52: 551-560. https://doi.org/10.1053/j.semnuclmed.2022.01.006

48. Guerra F, Giuliani G, Coletta D (2021) The risk of conversion in minimally invasive oncological abdominal surgery. Meta-analysis of randomized evidence comparing traditional laparoscopic versus robot-assisted techniques. Langenbeck's Arch Surg 406: 607-612. https://doi.org/10.1007/s00423-021-02106-y

49. Falagario U, Veccia A, Weprin S, Albuquerque EV, Nahas WC, et al. (2020) Robotic-assisted surgery for the treatment of urologic cancers: recent advances. Expert Rev Med Devices 17: 579-590. https://doi.org/10.1080/17434440.2020.1762487

50. Dhakad GG, Patil GD, Nikum AC, Shirsat SP (2022) Review on radiation therapy on cancer. Res J Pharmacol Pharmacodyn 14: 4-12. https://doi.org/10.52711/2321-5836.2022.00002

51. Lillo S, Mirandola A, Vai A, Camarda AM, Ronchi S, et al. (2024) Current status and future directions of proton therapy for head and neck carcinoma. Cancers 16: 2085. https://doi.org/10.3390/cancers16112085

52. Pojskic M, Naderi S, Vaishya S, Zileli M, Costa F, et al. (2024) Complication avoidance, rehabilitation, pain therapy and palliative care for patients with metastatic spine tumors: WFNS spine committee recommendations. Neurosurg Rev 47: 830. https://doi.org/10.1007/s10143-024-03050-3

53. Kumar AR, Devan AR, Nair B, Vinod BS, Nath LR (2021) Harnessing the immune system against cancer: current immunotherapy approaches and therapeutic targets. Mol Biol Rep 48: 8075-8095. https://doi.org/10.1007/s11033-021-06752-9

54. Behranvand N, Nasri F, Emameh RZ, Khani P, Hosseini A, et al. (2022) Chemotherapy: a double-edged sword in cancer treatment. Cancer Immunol Immunotherap 71: 507-526. https://doi.org/10.1007/s00262-021-03013-3

55. Anand U, Dey A, Chandel AK, Sanyal R, Mishra A, et al. (2023) Cancer chemotherapy and beyond: current status, drug candidates, associated risks and progress in targeted therapeutics. Gen Dis 10: 1367-1401. https://doi.org/10.1016/j.gendis.2022.02.007

56. Sunder SS, Sharma UC, Pokharel S (2023) Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management. Signal Transduct Target Ther 8: 262. https://doi.org/10.1038/s41392-023-01469-6

57. Ghemrawi R, Abuamer L, Kremesh S, Hussien G, Ahmed R, et al. (2024) Revolutionizing cancer treatment: recent advances in immunotherapy. Biomed 12: 2158. https://doi.org/10.3390/biomedicines12092158

58. Mitra A, Kumar A, Amdare NP, Pathak R (2024) Current landscape of cancer immunotherapy: harnessing the immune arsenal to overcome immune evasion. Biology 13: 307. https://doi.org/10.3390/biology13050307

59. Ritu, Chandra P, Das A (2023) Immune checkpoint targeting antibodies hold promise for combinatorial cancer therapeutics. Clin Exp Med 23: 4297-4322. https://doi.org/10.1007/s10238-023-01201-2

60. Lica JJ, Pradhan B, Safi K, Jakóbkiewicz-Banecka J, Hellmann A (2024) Promising therapeutic strategies for hematologic malignancies: innovations and potential. Molecules 29: 4280. https://doi.org/10.3390/molecules29174280

61. Raghani NR, Chorawala MR, Mahadik M, Patel RB, Prajapati BG, et al. (2024) Revolutionizing cancer treatment: comprehensive insights into immunotherapeutic strategies. Med Oncol 41: 51. https://doi.org/10.1007/s12032-023-02280-7

62. Xu M, Zhou L, Zheng L, Zhou Q, Liu K, et al. (2021) Sonodynamic therapy-derived multimodal synergistic cancer therapy. Cancer Lett 497: 229-242. https://doi.org/10.1016/j.canlet.2020.10.037

63. Conte M, Cauda V (2022) Multimodal therapies against pancreatic ductal adenocarcinoma: a review on synergistic approaches toward ultimate nanomedicine treatments. Adv Ther 5: 2200079. https://doi.org/10.1002/adtp.202200079

64. Allemailem KS, Alsahli MA, Almatroudi A, Alrumaihi F, Alkhaleefah FK, et al. (2022) Current updates of CRISPR/Cas9-mediated genome editing and targeting within tumor cells: an innovative strategy of cancer management. Cancer Commun 42: 1257-1287. https://doi.org/10.1002/cac2.12366

65. Malone ER, Oliva M, Sabatini PJB, Stockley TL, Siu LL (2020) Molecular profiling for precision cancer therapies. Genome Med 12: 1-19. https://doi.org/10.1186/s13073-019-0703-1

66. Duan XP, Qin BD, Jiao XD, Liu K, Wang Z, et al. (2024) New clinical trial design in precision medicine: discovery, development and direction. Signal Transduct Target Ther 9: 1-29. https://doi.org/10.1038/s41392-024-01760-0

67. Fountzilas E, Tsimberidou AM, Vo HH, Kurzrock R (2022) Clinical trial design in the era of precision medicine. Genome Med 14: 1-27. https://doi.org/10.1186/s13073-022-01102-1

68. Spreafico A, Hansen AR, Razak ARA, Bedard PL, Siu LL (2021) The future of clinical trial design in oncology. Cancer Discov 11: 822-837. https://doi.org/10.1158/2159-8290.cd-20-1301

69. Song IW, Vo HH, Chen YS, Baysal MA, Kahle M, et al. (2023) Precision oncology: evolving clinical trials across tumor types. Cancers (Basel) 15: 1967. https://doi.org/10.3390/cancers15071967

70. Huang Z, Chavda VP, Bezbaruah R, Dhamne H, Yang DH, et al. (2023) CAR T-cell therapy for the management of mantle cell lymphoma. Mol Cancer 22: 1-19. https://doi.org/10.1186/s12943-023-01755-5

71. Paz-Ares LG, Ramalingam SS, Ciuleanu TE, Lee JS, Urban L, et al. (2022) First-line nivolumab plus ipilimumab in advanced NSCLC: 4-year outcomes from the randomized, open-label, phase 3 checkmate 227 part 1 trial. J Thorac Oncol 17: 289-308. https://doi.org/10.1016/j.jtho.2021.09.010

72. Subbiah V, Burris HA, Kurzrock R (2024) Revolutionizing cancer drug development: Harnessing the potential of basket trials. Cancer 130: 186-200. https://doi.org/10.1002/cncr.35085

73. Tsimberidou AM, Müller P, Ji Y (2022) Innovative trial design in precision oncology. Semin Cancer Biol 84: 284-292. https://doi.org/10.1016/j.semcancer.2020.09.006

74. Haddad RI, Seiwert TY, Chow LQM, Gupta S, Weiss J, et al. (2022) Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma. J Immunother Cancer 10: 1-11. https://doi.org/10.1136/jitc-2021-003026

75. Ioachimescu OC, Shaker R (2024) Translational science and related disciplines. J Investig Med 73: 3-26. https://doi.org/10.1177/10815589241283515

76. Guin D, Thakran S, Singh P, Ramachandran S, Hasija Y, et al. (2021) Translational biotechnology: a transition from basic biology to evidence-based research. In Translational Biotechnology. Elsevier, pp 3-24.

77. Sanjeevi T (2024) Translational research platform for biomedical sciences: establishment and endeavors. In Translational Research in Biomedical Sciences: Recent Progress and Future Prospects. Springer Nature, Singapore, pp 183-190.

78. Mao X, Lee NK, Saad SE, Fong IL (2024) Clinical translation for targeting DNA damage repair in non-small cell lung cancer: a review. Transl Lung Cancer Res 13: 375-397. https://doi.org/10.21037/tlcr-23-742

79. Bhamidipati D, Haro-Silerio JI, Yap TA, Ngoi N (2023) PARP inhibitors: enhancing efficacy through rational combinations. Br J Cancer 129: 904-916. https://doi.org/10.1038/s41416-023-02326-7

80. Nolazco JI, Chang SL (2023) The role of health-related quality of life in improving cancer outcome. J Clin Transl Res 9: 110-14. https://doi.org/10.18053/jctres.09.202302.006

81. Rimmer B, Brown MC, Sotire T, Beyer F, Bolnykh I, et al. (2023) Characteristics and components of self-management interventions for improving quality of life in cancer survivors: a systematic review. Cancers (Basel) 16: 14. https://doi.org/10.3390/cancers16010014

82. Fabi A, Rossi A, Mocini E, Cardinali L, Bonavolontà V, et al. (2024) An integrated care approach to improve well-being in breast cancer patients. Curr Oncol Rep 26: 346-358. https://doi.org/10.1007/s11912-024-01500-1

83. Bakitas MA, Tosteson TD, Li Z, Lyons KD, Hull JG, et al. (2015) Early versus delayed initiation of concurrent palliative oncology care: patient outcomes in the ENABLE III randomized controlled trial. J Clin Oncol 33: 1438-1445. https://doi.org/10.1200/jco.2014.58.6362

84. Molina MC, Bueno CA, Redondo IC, Lucas-Torres MIL, López EJ, et al. (2024) Effectiveness of scalp cooling to prevent chemotherapy-induced alopecia in patients undergoing breast cancer treatment: a systematic review and meta-analysis. Cancer Nurs 47: 319-326. https://doi.org/10.1097/ncc.0000000000001234

85. Oyer RA, Hurley P, Boehmer L, Bruinooge SS, Levit K, et al. (2022) Increasing racial and ethnic diversity in cancer clinical trials: an American Society of Clinical Oncology and Association of Community Cancer Centers joint research statement. J Clin Oncol 40: 2163-2171. https://doi.org/10.1200/jco.22.00754

86. El-Deiry WS, Giaccone G (2021) Challenges in diversity, equity, and inclusion in research and clinical oncology. Front Oncol 11: 1-4. https://doi.org/10.3389/fonc.2021.642112

87. Patel D, Kilburn L, Fox L, Hall E, Bliss J, et al. (2023) Equality, diversity, and inclusion in oncology clinical trials: an audit of essential documents and data collection against INCLUDE under-served groups in a UK academic trial setting. BMC Med Ethics 24: 1-13. https://doi.org/10.1186/s12910-023-00987-w

88. TAILORx Trial Finds Most Women with Early Breast Cancer do not Benefit from Chemotherapy. National Institutes of Health. [https://www.nih.gov/news-events/news-releases/tailorx-trial-finds-most-women-early-breast-cancer-do-not-benefit-chemotherapy] [Accessed January 20, 2025]

89. Green AK, Trivedi N, Hsu JJ, Yu NL, Bach PB, et al. (2022) Despite the FDA's five-year plan, Black patients remain inadequately represented in clinical trials for drugs. Health Aff 41: 368-374. https://doi.org/10.1377/hlthaff.2021.01432

90. Loree JM, Anand S, Dasari A, Unger JM, Gothwal A, et al. (2019) Disparity of race reporting and representation in clinical trials leading to cancer drug approvals from 2008 to 2018. JAMA Oncol 5: e191870. https://doi.org/10.1001/jamaoncol.2019.1870

91. Ferrell BR, Temel JS, Temin S, Alesi ER, Balboni TA, et al. (2017) Integration of palliative care into standard oncology care: American society of clinical oncology clinical practice guideline update. J Clin Oncol 35: 96-112. https://doi.org/10.1200/jco.2016.70.1474

92. Patel MI, Lopez AM, Blackstock W, Reeder-Hayes K, Moushey EA, et al. (2020) Cancer disparities and health equity: a policy statement from the American Society of clinical oncology. J Clin Oncol 38: 3439-3448. https://doi.org/10.1200/jco.20.00642

93. Markham MJ, Wachter K, Agarwal N, Bertagnolli MM, Chang SM, et al. (2020) Clinical cancer advances 2020: annual report on progress against cancer from the American society of clinical oncology. J Clin Oncol 38: 1081. https://doi.org/10.1200/jco.19.03141

94. Morrison L, Loibl S, Turner NC (2024) The CDK4/6 inhibitor revolution - a game-changing era for breast cancer treatment. Nat Rev Clin Oncol 21: 89-105. https://doi.org/10.1038/s41571-023-00840-4

95. Al Meslamani AZ (2023) The future of precision medicine in oncology. Expert Rev Precis Med Drug Dev 8: 43-47. https://doi.org/10.1080/23808993.2023.2292988

96. Farina E, Nabhen JJ, Dacoregio MI, Batalini F, Moraes FY (2022) An overview of artificial intelligence in oncology. Futur Sci OA 8: FSO787. https://doi.org/10.2144/fsoa-2021-0074

97. Shimizu H, Nakayama KI (2020) Artificial intelligence in oncology. Cancer Sci 111: 1452-1460. https://doi.org/10.1111/cas.14377

98. Chua IS, Gaziel-Yablowitz M, Korach ZT, Kehl KL, Levitan NA, et al. (2021) Artificial intelligence in oncology: path to implementation. Cancer Med 10: 4138-4149. https://doi.org/10.1002/cam4.3935

99. Nikanjam M, Kato S, Kurzrock R (2022) Liquid biopsy: current technology and clinical applications. J Hematol Oncol 15: 1-14. https://doi.org/10.1186/s13045-022-01351-y

100. Im YR, Tsui DWY, Diaz LA, Wan JCM (2021) Next-generation liquid biopsies: embracing data science in oncology. Trends Cancer 7: 283-292. https://doi.org/10.1016/j.trecan.2020.11.001

101. Cescon DW, Bratman SV, Chan SM, Siu LL (2020) Circulating tumor DNA and liquid biopsy in oncology. Nat Cancer 1: 276-290. https://doi.org/10.1038/s43018-020-0043-5

102. Horgan D, Curigliano G, Rieß O, Hofman P, Büttner R, et al. (2022) Identifying the steps required to effectively implement next-generation sequencing in oncology at a national level in Europe. J Pers Med 12: 72. https://doi.org/10.3390/jpm12010072

103. Hussen BM, Abdullah ST, Salihi A, Sabir DK, Sidiq KR, et al. (2022) The emerging roles of NGS in clinical oncology and personalized medicine. Pathol Res Pract 230: 153760. https://doi.org/10.1016/j.prp.2022.153760

104. Marias K (2021) The constantly evolving role of medical image processing in oncology: from traditional medical image processing to imaging biomarkers and radiomics. J Imaging 7: 124. https://doi.org/10.3390/jimaging7080124

105. Jha AK, Mithun S, Purandare NC, Kumar R, Rangarajan V, et al. (2022) Radiomics: A quantitative imaging biomarker in precision oncology. Nucl Med Commun 43: 483-493. https://doi.org/10.1097/mnm.0000000000001543

106. Zhao Z, Li C, Tong F, Deng J, Huang G, et al. (2021) Review of applications of CRISPR-Cas9 gene-editing technology in cancer research. Biol Proced Online 23: 1-13. https://doi.org/10.1186/s12575-021-00151-x

107. Wang SW, Gao C, Zheng YM, Yi L, Lu JC, et al. (2022) Current applications and future perspective of CRISPR/Cas9 gene editing in cancer. Mol Cancer 21: 1-27. https://doi.org/10.1186/s12943-022-01518-8

108. Zhang H, Qin C, An C, Zheng X, Wen S, et al. (2021) Application of the CRISPR/Cas9-based gene editing technique in basic research, diagnosis, and therapy of cancer. Mol Cancer 20: 1-22. https://doi.org/10.1186/s12943-021-01431-6

109. Ding Z, Sigdel K, Yang L, Liu Y, Xuan M, et al. (2020) Nanotechnology-based drug delivery systems for enhanced diagnosis and therapy of oral cancer. J Mater Chem B 8: 8781-8793. https://doi.org/10.1039/d0tb00957a

110. Yan L, Shen J, Wang J, Yang X, Dong S, et al. (2020) Nanoparticle-based drug delivery system: a patient-friendly chemotherapy for oncology. Dose-Response 18. https://doi.org/10.1177/1559325820936161

111. Heidbuechel JPW, Engeland CE (2021) Oncolytic viruses encoding bispecific T cell engagers: a blueprint for emerging immunovirotherapies. J Hematol Oncol 14: 1-24. https://doi.org/10.1186/s13045-021-01075-5

112. Ugai T, Yao Q, Ugai S, Ogino S (2024) Advancing precision oncology: Insights into the tumor microenvironment and immunotherapy outcomes. Innovation 5: 100656. https://doi.org/10.1016/j.xinn.2024.100656

113. Wu Y, Zhou Y, Qin X, Liu Y (2021) From cell spheroids to vascularized cancer organoids: Microfluidic tumor-on-a-chip models for preclinical drug evaluations. Biomicrofluidics 15: 061503. https://doi.org/10.1063/5.0062697

114. Li W, Zhou Z, Zhou X, Khoo BL, Gunawan R, et al. (2023) 3D biomimetic models to reconstitute tumor microenvironment *in vitro*: spheroids, organoids, and tumor-on-a-chip. Adv Healthc Mater 12: 2202609. https://doi.org/10.1002/adhm.202202609

115. Beg S, Handa M, Shukla R, Rahman M, Almalki WH, et al. (2022) Wearable smart devices in cancer diagnosis and remote clinical trial monitoring: transforming healthcare applications. Drug Discov Today 27: 103314. https://doi.org/10.1016/j.drudis.2022.06.014

116. Pavic M, Klaas V, Theile G, Kraft J, Tröster G, et al. (2020) Feasibility and usability aspects of continuous remote monitoring of health status in palliative cancer patients using wearables. Oncol 98: 386-395. https://doi.org/10.1159/000501433

117. McGregor BA, Vidal GA, Shah SA, Mitchell JD, Hendifar AE (2020) Remote oncology care: review of current technology and future directions. Cureus 12: e10156. https://doi.org/10.7759/cureus.10156

118. Jain S, Ziauddin J, Leonchyk P, Yenkanchi S, Geraci J (2020) Quantum and classical

machine learning for the classification of non-small-cell lung cancer patients. SN Appl Sci 2: 1-10. https://doi.org/10.1007/s42452-020-2847-4

119. Iyer V, Ganti B, Vyshnavi AMH, Namboori PKK, Iyer S (2020) Hybrid quantum computing based early detection of skin cancer. J Interdiscip Math 23: 347-355. https://doi.org/10.1080/09720502.2020.1731948

120. Vanbutsele G, Van Belle S, Surmont V, De Laat M, Colman R, et al. (2020) The effect of early and systematic integration of palliative care in oncology on quality of life and health care use near the end of life: a randomised controlled trial. Eur J Cancer 124: 186-193. https://doi.org/10.1016/j.ejca.2019.11.009

121. Gao W, Wilson R, Hepgul N, Yi D, Evans C, et al. (2020) Effect of short-term integrated palliative care on patient-reported outcomes among patients severely affected with long-term neurological conditions: a randomized clinical trial. JAMA Netw Open 3: e2015061. https://doi.org/10.1001/jamanetworkopen.2020.15061

122. Petrillo LA, Jones KF, El-Jawahri A, Sanders J, Greer JA, et al. (2024) Why and how to integrate early palliative care into cutting-edge personalized cancer care. Am Soc Clin Oncol Educ B 44: e100038. https://doi.org/10.1200/edbk_100038

123. Goswami S, Ghosh D, Nandi G, Mukherjee S, Sarkar B (2022) Pain management in oncology. In Cancer Diagnostics and Therapeutics: Current Trends, Challenges, and Future Perspectives. Springer, Singapore, pp 333-373.

124. Mestdagh F, Steyaert A, Lavand'homme P (2023) Cancer pain management: a narrative review of current concepts, strategies, and techniques. Curr Oncol 30: 6838-6858. https://doi.org/10.3390/curroncol30070500

125. Lopes-Júnio LC, Tuma MC, Amorim MHC (2021) Psychoneuroimmunology and oncology nursing: theoretical study. Rev Esc Enferm USP 55: 1-9. https://doi.org/10.1590/1980-220X-REEUSP-2021-0159

126. Estrela M, Herdeiro MT, Ferreira PL, Roque F (2020) The use of antidepressants, anxiolytics, sedatives and hypnotics in Europe: focusing on mental health care in Portugal and prescribing in older patients. Int J Environ Res Public Health 17: 1-12. https://doi.org/10.3390/ijerph17228612

127. Rodin G, An E, Shnall J, Malfitano C (2020) Psychological interventions for patients with advanced disease: implications for oncology and palliative care. J Clin Oncol 38: 885-904. https://doi.org/10.1200/jco.19.00058

128. Zacharia M, Karekla M (2022) The role of psychologists and psychological approaches in cancer care. In Handbook of Quality of Life in Cancer. Springer, Cham, pp 311-337.

129. Links MJ, Watterson L, Martin P, O'Regan S, Molloy E (2020) Finding common ground: meta-synthesis of communication frameworks found in patient communication, supervision and simulation literature. BMC Med Educ 20: 1-16. https://doi.org/10.1186/s12909-019-1922-2

130. Reifarth E, Borrega JG, Kochanek M (2023) How to communicate with family members of the critically ill in the intensive care unit: a scoping review. Intensive Crit Care Nurs 74: 103328. https://doi.org/10.1016/j.iccn.2022.103328

131. Groenewoud AS, Wichmann AB, Dijkstra L, Knapen E, Warmerdam F, et al. (2021) Effects of an integrated palliative care pathway: more proactive GPs, well timed, and less acute care: a clustered, partially controlled before-after study. J Am Med Dir Assoc 22: 297-304. https://doi.org/10.1016/j.jamda.2020.10.025

132. Kayastha N, LeBlanc TW (2020) When to integrate palliative care in the trajectory of cancer care. Curr Treat Options Oncol 21: 1-13. https://doi.org/10.1007/s11864-020-00743-x

133. Mao JJ, Pillai GG, Andrade CJ, Ligibel JA, Basu P, et al. (2022) Integrative oncology: Addressing the global challenges of cancer prevention and treatment. CA Cancer J Clin 72: 144-164. https://doi.org/10.3322/caac.21706

134. Soerjomataram I, Bray F (2021) Planning for tomorrow: global cancer incidence and the role of prevention 2020–2070. Nat Rev Clin Oncol 18: 663-672. https://doi.org/10.1038/s41571-021-00514-z

135. Schiller JT, Lowy DR (2021) An introduction to virus infections and human cancer. In Recent Results in Cancer Research. Springer, Cham, pp 1-11.

136. Constable C, Caplan A (2020) Comparison of the implementation of human papillomavirus and hepatitis B vaccination programs in the United States: implications for future vaccines. Vaccine 38: 954-962. https://doi.org/10.1016/j.vaccine.2019.11.073

137. Horgan D, Baird AM, Middleton M, Mihaylova Z, Van Meerbeeck JP, et al. (2022) How can the EU beating cancer plan help in tackling lung cancer, colorectal cancer, breast cancer and melanoma? Healthcare (Basel) 10: 1618. https://doi.org/10.3390/healthcare10091618

138. Ballard DH, Burton KR, Lakomkin N, Kim S, Rajiah P, et al. (2021) The role of imaging in health screening: screening for specific conditions. Acad Radiol 28: 548-563. https://doi.org/10.1016/j.acra.2020.03.039

139. Patel SG, May FP, Anderson JC, Burke CA, Dominitz JA, et al. (2022) Updates on age to start and stop colorectal cancer screening: recommendations from the U.S. multi-society task force on colorectal cancer. Gastroenterology 162: 285-299. https://doi.org/10.14309/ajg.0000000000001548

140. Trivedi MS, Armstrong KA (2024) Increasing the uptake of cancer risk management strategies for women with BRCA1/2 sequence variations. JAMA Oncol 10: 435-436. https://doi.org/10.1001/jamaoncol.2023.5186

141. Sorouri K, Lynce F, Feltmate CM, Davis MR, Muto MG, et al. (2023) Endometrial cancer risk among germline BRCA1/ 2 pathogenic variant carriers: review of our current understanding and next steps. JCO Precis Oncol 7: 1-9. https://doi.org/10.1200/po.23.00290

142. Hendrick RE, Helvie MA (2011) United States preventive services task force screening mammography recommendations: science ignored. Am J Roentgenol 196: W112-W116. https://doi.org/10.2214/ajr.10.5609

143. Sun D, Li H, Cao M, He S, Lei L, et al. (2020) Cancer burden in China: trends, risk factors and prevention. Cancer Biol Med 17: 879-895. https://doi.org/10.20892/j.issn.2095-3941.2020.0387

144. Goodman S, Chappell G, Guyton KZ, Pogribny IP, Rusyn I (2022) Epigenetic alterations induced by genotoxic occupational and environmental human chemical carcinogens: a update of a systematic literature review. Mutat Res Rev Mutat Res 768: 27-45. https://doi.org/10.1016/j.mrrev.2016.03.004

145. Wadgaonkar P (2024) Environmental causes of cancer. In Cancer Epigenetics and Nanomedicine: Targeting the Right Player via Nanotechnology. Academic Press, pp 69-92.

146. Gholami S, Behnami A, Benis KZ (2024) Air pollution and cancer. In Diseases and Health Consequences of Air Pollution, Volume 3: Air Pollution, Human Health, and the Environment. Academic Press, pp 85-108.

147. Zhao Z, Li J, Tan F, Xue Q, Gao S, et al. (2024) Assessing the global burden of mesothelioma: trends, socioeconomic influences, and asbestos exposure-a retrospective cohort study. Int J Surg111: 93-103. https://doi.org/10.1097/js9.0000000000001900

148. Haier J, Schaefers J (2022) Economic perspective of cancer care and its consequences for vulnerable groups. Cancers (Basel) 14: 3158. https://doi.org/10.3390/cancers14133158

149. Tordrup D, Smith R, Kamenov K, Bertram MY, Green N, et al. (2022) Global return on investment and cost-effectiveness of WHO's HEAR interventions for hearing loss: a modelling study. Lancet Glob Health 10: e52-e62. https://doi.org/10.1016/s2214-109x(21)00447-2

150. Ramadan M, Alhusseini N, Samhan L, Samhan S, Abbad T (2023) Tobacco control policies implementation and future lung cancer incidence in Saudi Arabia. A population-based study. Prev Med Rep 36: 102439. https://doi.org/10.1016/j.pmedr.2023.102439

151. Ringborg U, von Braun J, Celis J, Baumann M, Berns A, et al. (2024) Strategies to decrease inequalities in cancer therapeutics, care and prevention: proceedings on a conference organized by the Pontifical Academy of Sciences and the European Academy of Cancer Sciences, Vatican City, February 23-24, 2023. Mol Oncol 18: 245-279. https://doi.org/10.1002/1878-0261.13575

152. Hemati H, Patrinos GP, Meybodi HRA, Sarhangi N, Larijani B, et al. (2024) Introduction to the future of medicine. In A Glimpse at Medicine in the Future. Springer Nature, Singapore, pp 1-20.

153. Astromskė K, Peičius E, Astromskis P (2021) Ethical and legal challenges of informed consent applying artificial intelligence in medical diagnostic consultations. AI Soc 36: 509-520. https://doi.org/10.1007/s00146-020-01008-9

154. Zhang J, Zhang ZM (2023) Ethics and governance of trustworthy medical artificial intelligence. BMC Med Inform Decis Mak 23: 1-15. https://doi.org/10.1186/s12911-023-02103-9

155. Franzoi MA, Agostinetto E, Perachino M, Del Mastro L, de Azambuja E, et al. (2021) Evidence-based approaches for the management of side-effects of adjuvant endocrine therapy in patients with breast cancer. Lancet Oncol 22: e303-e313. https://doi.org/10.1016/s1470-2045(20)30666-5

156. Ng PC, Fung GPG (2023) Spiritual and cultural influences on end-of-life care and decision-making in NICU. Semin Fetal Neonatal Med 28: 101437. https://doi.org/10.1016/j.siny.2023.101437

157. Gallagher CM, Moore JA, Roberts AH (2019) Ethical issues at the end-of-life in the cancer patient. In Oncologic Critical Care. Springer, Cham, pp 1937-1962.

158. Foo KF, Lin YP, Lin CP, Chen YC (2024) Fostering relational autonomy in end-of-life care: a procedural approach and three-dimensional decision-making model. J Med Ethics 2024. https://doi.org/10.1136/jme-2023-109818

159. Horrill TC, Browne AJ, Stajduhar KI (2022) Equity-oriented healthcare: what it is and why we need it in oncology. Curr Oncol 29: 186-192. https://doi.org/10.3390/curroncol29010018

160. Zahnd WE, Murphy C, Knoll M, Benavidez GA, Day KR, et al. (2021) The intersection of rural residence and minority race/ethnicity in cancer disparities in the United States. Int J Environ Res Public Health 18: 1-27. https://doi.org/10.3390/ijerph18041384

161. Adeniji AA, Dulal S, Martin MG (2021) Personalized medicine in oncology in the developing world: barriers and concepts to improve status quo. World J Oncol 12: 50-60. https://doi.org/10.14740/wjon1345

162. Call CC, Eckstrand KL, Kasparek SW, Boness CL, Blatt L, et al.(2023) An ethics and social-justice approach to collecting and using demographic data for psychological researchers. Perspect Psychol Sci 18: 979-995. https://doi.org/10.1177/17456916221137350

163. Versavel S, Subasinghe A, Johnson K, Golonski N, Muhlhausen J, et al. (2023) Diversity, equity, and inclusion in clinical trials: a practical guide from the perspective of a trial sponsor. Contemp Clin Trials 126: 107092. https://doi.org/10.1016/j.cct.2023.107092

164. Bertolaccini L, Casiraghi M, Uslenghi C, Maiorca S, Spaggiari L (2024) Recent advances in lung cancer research: unravelling the future of treatment. Updates Surg 76: 2129-2140. https://doi.org/10.1007/s13304-024-01841-3

165. Eini M, Zainodini N, Montazeri H, Mirzabeigi P, Tarighi P (2021) A review of therapeutic antibodies in breast cancer. J Pharm Pharm Sci 24: 363-380. https://doi.org/10.18433/jpps31864

166. Steinmann G, Daniels K, Mieris F, Delnoij D, van de Bovenkamp H, et al. (2022) Redesigning value-based hospital structures: a qualitative study on value-based health care in the Netherlands. BMC Health Serv Res 22: 1-14. https://doi.org/10.1186/s12913-022-08564-4

167. Taylor DG (2020) The political economics of cancer drug discovery and pricing. Drug Discov Today 25: 2149-2160. https://doi.org/10.1016/j.drudis.2020.09.007

168. Godman B, Hill A, Simoens S, Selke G, Krulichová I S, et al. (2021) Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications. Expert Rev Pharmacoecon Outcomes Res 21: 527-540. https://doi.org/10.1080/14737167.2021.1884546

169. Manders EA, van den Berg S, de Visser SJ, Hollak CEM (2024) Drug pricing models, no 'one-size-fits-all' approach: a systematic review and critical evaluation of pricing models in an evolving pharmaceutical landscape. Eur J Health Econ 2024: 1-14. https://doi.org/10.1007/s10198-024-01731-w

170. Khanna S, Srivastava S, Khanna I, Pandey V (2020) Ethical challenges arising from the integration of artificial intelligence (AI) in oncological management. Int J Responsible Artif Intell 10: 34-44.

171. Cawthorne D, Wynsberghe AR (2020) An ethical framework for the design, development, implementation, and assessment of drones used in public healthcare. Sci Eng Ethics 26: 2867-2891. https://doi.org/10.1007/s11948-020-00233-1

172. Lunt N (2023) The global challenge of cancer governance. World Med Health Policy 15: 672-681. https://doi.org/10.1002/wmh3.577

173. Vrinzen CEJ, Bloemendal HJ, Jeurissen PPT (2023) How to create value with constrained budgets in oncological care? A narrative review. Expert Rev Pharmacoecon Outcomes Res 23: 989-999. https://doi.org/10.1080/14737167.2023.2253375

174. Boscolo PR, Callea G, Ciani O, Tarricone R (2020) Measuring value in health care: a comparative analysis of value-based frameworks. Clin Ther 42: 34-43. https://doi.org/10.1016/j.clinthera.2019.11.017